Shane Cooke
CIK: 0001524823
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- May 21, 2026ALKS
Alkermes plc.
Tax Payment(F)Direct3.2K shares at avg. $36.95$118K - May 21, 2026ALKS
Alkermes plc.
Exercise(M)Direct6.1K shares- - May 20, 2026ALKS
Alkermes plc.
Award(A)DirectNon Qualified Stock Option (Right to Buy)
11.5K shares- - May 20, 2026ALKS
Alkermes plc.
Award(A)DirectRestricted Stock Unit Award
5.4K shares- - May 20, 2026ALKS
Alkermes plc.
Award(A)DirectRestricted Stock Unit Award
5.4K shares- - May 20, 2026ALKS
Alkermes plc.
Award(A)DirectNon Qualified Stock Option (Right to Buy)
11.5K shares- - May 15, 2026PRTA
PROTHENA CORP PUBLIC LTD CO
Award(A)DirectStock Option (Right to Buy)
27K shares- - Feb 2, 2026ALKS
Alkermes plc.
Sale(S)Direct32.1K shares at avg. $34.78$1.1M - Feb 2, 2026ALKS
Alkermes plc.
Sale(S)Direct29.1K shares at avg. $34.34$999K - Feb 2, 2026ALKS
Alkermes plc.
Exercise(M)Direct61.2K shares at avg. $31.64$1.9M - May 31, 2025ALKS
Alkermes plc.
Exercise(M)Direct8K shares- - May 31, 2025ALKS
Alkermes plc.
Tax Payment(F)Direct4.2K shares at avg. $30.61$128K - May 21, 2025ALKS
Alkermes plc.
Award(A)DirectRestricted Stock Unit Award
6.1K shares- - May 21, 2025ALKS
Alkermes plc.
Award(A)DirectNon Qualified Stock Option (Right to Buy)
13.5K shares- - May 14, 2025PRTA
PROTHENA CORP PUBLIC LTD CO
Award(A)DirectStock Option (Right to Buy)
20.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 21, 2026 |  ALKS Alkermes plc. | Tax Payment(F) | 3,207 | $36.95 | $118,499 | Direct |
| May 21, 2026 | ALKS Alkermes plc. | Exercise(M) | 6,142 | - | $0 | Direct |
| May 20, 2026 | ALKS Alkermes plc. | Award(A) Non Qualified Stock Option (Right to Buy) | 11,538 | - | - | Direct |
| May 20, 2026 | ALKS Alkermes plc. | Award(A) Restricted Stock Unit Award | 5,409 | - | - | Direct |
| May 20, 2026 | ALKS Alkermes plc. | Award(A) Restricted Stock Unit Award | 5,409 | - | - | Direct |
| May 20, 2026 | ALKS Alkermes plc. | Award(A) Non Qualified Stock Option (Right to Buy) | 11,538 | - | - | Direct |
| May 15, 2026 |  PRTA PROTHENA CORP PUBLIC LTD CO | Award(A) Stock Option (Right to Buy) | 27,000 | - | - | Direct |
| Feb 2, 2026 | ALKS Alkermes plc. | Sale(S) | 32,113 | $34.78 | $1,116,877 | Direct |
| Feb 2, 2026 | ALKS Alkermes plc. | Sale(S) | 29,087 | $34.34 | $998,795 | Direct |
| Feb 2, 2026 | ALKS Alkermes plc. | Exercise(M) | 61,200 | $31.64 | $1,936,368 | Direct |
| May 31, 2025 | ALKS Alkermes plc. | Exercise(M) | 8,013 | - | - | Direct |
| May 31, 2025 | ALKS Alkermes plc. | Tax Payment(F) | 4,175 | $30.61 | $127,797 | Direct |
| May 21, 2025 | ALKS Alkermes plc. | Award(A) Restricted Stock Unit Award | 6,142 | - | - | Direct |
| May 21, 2025 | ALKS Alkermes plc. | Award(A) Non Qualified Stock Option (Right to Buy) | 13,474 | - | - | Direct |
| May 14, 2025 | PRTA PROTHENA CORP PUBLIC LTD CO | Award(A) Stock Option (Right to Buy) | 20,183 | - | - | Direct |
1-15 of 15 transactions
About Cooke Shane
Cooke Shane (SEC CIK 0001524823) files insider reports with the SEC as Director of Alkermes plc. (ALKS) and Director of PROTHENA CORP PUBLIC LTD CO (PRTA).
Signal8 holds 7 ownership filings by Cooke Shane, all Form 4s, filed between May 16, 2025 and May 22, 2026. Those filings report 15 transactions, from May 14, 2025 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cooke Shane's filings is in DUBLIN.
Recent filings by Cooke Shane
- May 21, 2026: Tax withholding of ALKS shares (Form 4, code F).
- May 21, 2026: Option exercise of ALKS shares (Form 4, code M).
- May 20, 2026: Grants or awards of ALKS derivative securities (4 lines, Form 4, code A).
- May 15, 2026: Grant or award of PRTA derivative securities (Form 4, code A).
- Feb 2, 2026: Open-market sales of ALKS shares (2 lines, Form 4, code S).
Other insiders filing for Alkermes plc. (ALKS)
- Gaffin David Joseph, EVP, CLO, Alkermes, Inc.
- Reed Joshua, SVP, Chief Financial Officer
- Whitaker Anne Clem, Director
- Hopkinson Craig C., EVP R&D, Chief Medical Officer
- Nichols Christian Todd, SVP, Chief Commercial Officer
- Jackson Blair Curtis, President & CEO, Alkermes plc